4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group

1. A compound of formula (I)

wherein:

R 1 is a group selected from C 1 -C 6 -alkyl-, C 3 -C 7 -cycloalkyl-, heterocyclyl-, phenyl, heteroraryl, phenyl-C 1 -C 3 -alkyl-, and heteroaryl-C 1 -C 3 -alkyl-,

wherein said group is optionally substituted with one or two or three substituents, identically or differently, selected from the group consisting of hydroxy, cyano, halogen, halo-C 1 -C 3 -alkyl-, C 1 -C 6 -alkoxy-, C 1 -C 3 -fluoroalkoxy-, amino, alkylamino-, dialkylamino-, acetylamino-, N-methyl-N-acetylamino-, and cyclic amines;

R 2 is a group selected from

R 3 and R 4 are independently a group selected from a hydrogen atom, fluoro atom, chloro atom, cyano, C 1 -C 3 -alkyl-, C 1 -C 3 -alkoxy-, halo-C 1 -C 3 -alkyl-, and C 1 -C 3 -fluoroalkoxy-;

R 5 is a group selected from a hydrogen atom, cyano, —C(O)R 9 , —C(O)OR 9 , —S(O) 2 R 9 , —C(O)NR 10 R 11 , C 1 -C 6 -alkyl-, C 3 -C 7 -cycloalkyl-, heterocyclyl-, phenyl, and heteroaryl,

wherein said C 1 -C 6 -alkyl-, C 3 -C 7 -cycloalkyl-, heterocyclyl-, phenyl or heteroaryl group is optionally substituted with one, two or three substituents, identically or differently, selected from halogen, cyano, hydroxy, C 1 -C 3 -alkyl-, C 1 -C 3 -alkoxy-, amino, alkylamino-, dialkylamino-, acetylamino-, N-methyl-N-acetylamino-, cyclic amines, halo-C 1 -C 3 -alkyl-, and C 1 -C 3 -fluoroalkoxy-;

R 6 and R 7 are independently a group selected from a hydrogen atom, fluoro atom, chloro atom, cyano, C 1 -C 3 -alkyl-, C 1 -C 3 -alkoxy-, halo-C 1 -C 3 -alkyl-, and C 1 -C 3 -fluoroalkoxy-;

R 8 is a group selected from

a) a C 1 -C 10 -alkyl group, which is optionally substituted with one or two or three substituents, identically or differently, selected from the group consisting of halogen, hydroxy, amino, alkylamino-, dialkylamino-, acetylamino-, N-methyl-N-acetylamino-, cyclic amines, cyano, C 1 -C 3 -alkyl-, halo-C 1 -C 3 -alkyl-, C 1 -C 3 -fluoroalkoxy-, C 1 -C 3 -alkoxy-, C 2 -C 3 -alkenyl-, C 2 -C 3 -alkynyl-, C 3 -C 7 -cycloalkyl-, heterocyclyl-, phenyl, and heteroaryl,

wherein said C 3 -C 7 -cycloalkyl-, heterocyclyl-, phenyl or heteroaryl group is optionally substituted with one, two or three substituents, identically or differently, selected from halogen, hydroxy, cyano, C 1 -C 3 -alkyl-, C 1 -C 3 -alkoxy-, amino, alkylamino-, dialkylamino-, acetylamino-, N-methyl-N-acetylamino-, cyclic amines, halo-C 1 -C 3 -alkyl-, and C 1 -C 3 -fluoroalkoxy-;

b) a C 3 -C 7 -cycloalkyl- group, which is optionally substituted with one or two or three substituents, identically or differently, selected from the group consisting of halogen, hydroxy, amino, alkylamino-, dialkylamino-, acetylamino-, N-methyl-N-acetylamino-, cyclic amines, cyano, C 1 -C 3 -alkyl-, halo-C 1 -C 3 -alkyl-, C 1 -C 3 -fluoroalkoxy-, C 1 -C 3 -alkoxy-, C 2 -C 3 -alkenyl-, and C 2 -C 3 -alkynyl-;

c) a heterocyclyl- group, which is optionally substituted with one or two or three substituents, identically or differently, selected from the group consisting of halogen, hydroxy, amino, alkylamino-, dialkylamino-, acetylamino-, N-methyl-N-acetylamino-, cyclic amines, cyano, C 1 -C 3 -alkyl-, halo-C 1 -C 3 -alkyl-, C 1 -C 3 -fluoroalkoxy-, C 1 -C 3 -alkoxy-, C 2 -C 3 -alkenyl-, and C 2 -C 3 -alkynyl-;

d) a phenyl group, which is optionally substituted with one or two or three substituents, identically or differently, selected from the group consisting of halogen, hydroxy, amino, alkylamino-, dialkylamino-, acetylamino-, N-methyl-N-acetylamino-, cyclic amines, cyano, C 1 -C 3 -alkyl-, halo-C 1 -C 3 -alkyl-, C 1 -C 3 -fluoroalkoxy-, and C 1 -C 3 -alkoxy-;

e) a heteroaryl group, which is optionally substituted with one or two or three substituents, identically or differently, selected from the group consisting of halogen, hydroxy, amino, alkylamino-, dialkylamino-, acetylamino-, N-methyl-N-acetylamino-, cyclic amines, cyano, C 1 -C 3 -alkyl-, halo-C 1 -C 3 -alkyl-, C 1 -C 3 -fluoroalkoxy-, and C 1 -C 3 -alkoxy-;

f) a phenyl-C 1 -C 3 -alkyl- group, which is optionally substituted with one or two or three substituents, identically or differently, selected from the group consisting of halogen, hydroxy, amino, alkylamino-, dialkylamino-, acetylamino-, N-methyl-N-acetylamino-, cyclic amines, cyano, C 1 -C 3 -alkyl-, halo-C 1 -C 3 -alkyl-, C 1 -C 3 -fluoroalkoxy-, and C 1 -C 3 -alkoxy-; and

g) a heteroaryl-C 1 -C 3 -alkyl- group, which is optionally substituted with one or two or three substituents, identically or differently, selected from the group consisting of halogen, hydroxy, amino, alkylamino-, dialkylamino-, acetylamino-, N-methyl-N-acetylamino-, cyclic amines, cyano, C 1 -C 3 -alkyl-, halo-C 1 -C 3 -alkyl-, C 1 -C 3 -fluoroalkoxy-, and C 1 -C 3 -alkoxy-;

R 9 is a group selected from C 1 -C 6 -alkyl-, C 3 -C 7 -cycloalkyl-, heterocyclyl-, phenyl, benzyl and heteroaryl, wherein said group is optionally substituted with one, two or three substituents, identically or differently, selected from halogen, hydroxy, C 1 -C 3 -alkyl-, C 1 -C 3 -alkoxy-, amino, alkylamino-, dialkylamino-, acetylamino-, N-methyl-N-acetylamino-, cyclic amines, halo-C 1 -C 3 -alkyl-, and C 1 -C 3 -fluoroalkoxy-; and

R 10 and R 11 are independently a group selected from hydrogen, C 1 -C 6 -alkyl-, C 3 -C 7 -cycloalkyl-, heterocyclyl-, phenyl and heteroaryl, wherein said C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl-, heterocyclyl-, phenyl or heteroaryl group is optionally substituted with one, two or three substituents, identically or differently, selected from halogen, hydroxy, C 1 -C 3 -alkyl-, C 1 -C 3 -alkoxy-, amino, alkylamino-, dialkylamino-, acetylamino-, N-methyl-N-acetylamino-, cyclic amines, halo-C 1 -C 3 -alkyl-, and C 1 -C 3 -fluoroalkoxy-,

or a salt or solvate thereof, or a salt of the solvate thereof.

2. The compound according to claim 1 , wherein:

R 1 is a group selected from C 1 -C 6 -alkyl-, C 3 -C 7 -cycloalkyl- and heterocyclyl-;

R 2 is a group selected from

R 3 and R 4 are independently a group selected from a hydrogen atom, fluoro atom, chloro atom and C 1 -C 3 -alkyl-;

R 5 is a group selected from a hydrogen atom, cyano, —C(O)R 9 , —C(O)OR 9 , —S(O) 2 R 9 , —C(O)NR 10 R 11 , and C 1 -C 6 -alkyl-;

R 6 and R 7 are independently a group selected from a hydrogen atom, fluoro atom, and chloro atom;

R 8 is a group selected from

a) a C 1 -C 10 -alkyl group, which is optionally substituted with one or two or three substituents, selected from the group consisting of halogen, hydroxy, C 2 -C 3 -alkenyl-, C 2 -C 3 -alkynyl-, C 3 -C 7 -cycloalkyl-, heterocyclyl-, phenyl, and heteroaryl,

wherein said C 3 -C 7 -cycloalkyl-, heterocyclyl-, phenyl or heteroaryl group is optionally substituted with one, two or three substituents, identically or differently, selected from halogen, cyano, C 1 -C 3 -alkyl-, and halo-C 1 -C 3 -alkyl-;

b) a phenyl group;

c) a phenyl-C 1 -C 3 -alkyl- group, the phenyl group of which is optionally substituted with one or two or three substituents, identically or differently, selected from the group consisting of halogen, cyano, C 1 -C 3 -alkyl-, and halo-C 1 -C 3 -alkyl-; and

d) a heteroaryl-C 1 -C 3 -alkyl- group, the heteroaryl group of which is optionally substituted with one halogen;

R 9 is a C 1 -C 6 -alkyl group; and

R 10 and R 11 are independently a group selected from hydrogen and C 1 -C 6 -alkyl-,

or a salt or solvate thereof, or a salt of the solvate thereof.

3. The compound according to claim 1 , which is of formula (Ia)

wherein:

R 1 is a C 1 -C 6 -alkyl- or C 3 -C 7 -cycloalkyl- group;

R 2 is a group selected from

R 3 and R 4 are independently a group selected from a hydrogen atom, fluoro atom, chloro atom, and C 1 -C 3 -alkyl-;

R 5 is a group selected from a hydrogen atom, cyano, —C(O)R 9 , —C(O)OR 9 , and —C(O)NR 10 R 11 ;

R 6 and R 7 are independently a hydrogen atom or fluoro atom;

R 8 is a group selected from

a) a C 1 -C 10 -alkyl group, which is optionally substituted with one or two substituents, selected from the group consisting of hydroxy, C 2 -C 3 -alkenyl-, C 2 -C 3 -alkynyl-, C 3 -C 7 -cycloalkyl-, phenyl, and heteroaryl,

wherein said C 3 -C 7 -cycloalkyl-, phenyl or heteroaryl group is optionally substituted with one, two or three substituents, identically or differently, selected from halogen, cyano, and halo-C 1 -C 3 -alkyl-;

b) a phenyl-C 1 -C 3 -alkyl- group, the phenyl group of which is optionally substituted with one or two or three substituents, identically or differently, selected from the group consisting of halogen, cyano, and halo-C 1 -C 3 -alkyl-; and

c) a heteroaryl-C 1 -C 3 -alkyl- group, the heteroaryl group of which is optionally substituted with one halogen;

R 9 is a C 1 -C 6 -alkyl group; and

R 10 and R 11 are independently a group selected from hydrogen and C 1 -C 6 -alkyl-,

or a salt or solvate thereof, or a salt of the solvate thereof.

4. The compound according to claim 1 , which is of formula (Ia)

wherein:

R 1 is methyl;

R 2 is a group selected from 4-fluoro-2-methoxyphenyl-, 2-(benzyloxy)-4-fluorophenyl-, 4,5-difluoro-2-methoxyphenyl-, 2-[(4-fluorobenzyl)oxy]phenyl-, and 4-fluoro-2-[(4-fluorobenzyl)oxy]phenyl;

R 3 is a group selected from a hydrogen atom, fluoro atom, and chloro atom;

R 4 is a group selected from a hydrogen atom and chloro atom;

R 5 is a group selected from a hydrogen atom, —C(O)R 9 , and —C(O)OR 9 ; and

R 9 is a group selected from methyl and ethyl,

or a salt or solvate thereof, or a salt of the solvate thereof.

5. The compound according to claim 1 , which is of formula (Ia)

wherein:

R 1 is methyl;

R 2 is a group selected from 4-fluoro-2-methoxyphenyl- and 4,5-difluoro-2-methoxyphenyl-;

R 3 and R 4 are each a hydrogen atom; and

R 5 is a hydrogen atom,

or a salt or solvate thereof, or a salt of the solvate thereof.

6. The compound according to claim 1 , wherein:

R 1 is a group selected from methyl, ethyl, cyclopropyl, and tetrahydro-2H-pyranyl-;

R 2 is a group selected from

R 3 and R 4 are independently a group selected from a hydrogen atom, fluoro atom, chloro atom and methyl;

R 5 is a group selected from a hydrogen atom, cyano, —C(O)R 9 , —C(O)OR 9 , —S(O) 2 R 9 , —C(O)NR 10 R 11 , and C 1 -C 6 -alkyl-;

R 6 and R 7 are independently a group selected from a hydrogen atom, fluoro atom, and chloro atom;

R 8 is a group selected from

a) a methyl, ethyl, propyl or butyl group, wherein said group is optionally substituted with one or two or three substituents, selected from the group consisting of halogen, hydroxy, ethenyl, propenyl, ethynyl-, propynyl-, cyclopentyl-, cyclohexyl, tetrahydro-2H-pyranyl-, phenyl, pyridinyl-, thiazolyl-, and oxazolyl,

wherein said phenyl or pyridinyl- group is optionally substituted with one, two or three substituents, identically or differently, selected from a fluoro atom, chloro atom, cyano, methyl, and trifluoromethyl;

b) a ( 2 H 2 )methyl group substituted with a ( 2 H 5 )phenyl group;

c) a phenyl group;

d) a benzyl group, the phenyl ring of which is optionally substituted with one or two or three substituents, identically or differently, selected from the group consisting of a fluoro atom, chloro atom, cyano, methyl and trifluoromethyl-;

e) a pyridin-2-ylmethyl- group, wherein the pyridin- moiety is optionally substituted with one fluoro atom;

f) a pyridin-3-ylmethyl- group, wherein the pyridin- moiety is optionally substituted with one fluoro atom;

g) a pyridin-4-ylmethyl- group, wherein the pyridin- moiety is optionally substituted with one fluoro atom;

h) a thiazolylmethyl- group; and

i) an oxazolylmethyl- group;

R 9 is a methyl or ethyl group; and

R 10 and R 11 are independently from each other, a group selected from hydrogen and methyl,

or a salt or solvate thereof, or a salt of the solvate thereof.

7. The compound according to claim 1 , wherein:

R 1 is a methyl, ethyl or cyclopropyl group;

R 2 is a group selected from

R 3 is a group selected from a hydrogen atom, fluoro atom, chloro atom and methyl;

R 4 is a group selected from a hydrogen atom and fluoro atom;

R 5 is a group selected from a hydrogen atom, cyano, —C(O)R 9 , —C(O)OR 9 , and C(O)NR 10 R 11 ;

R 6 and R 7 are independently from each other, a group selected from a hydrogen atom and fluoro atom;

R 8 is a group selected from

methyl, ethyl, prop-2-en-1-yl-, 2-methylprop-2-en-1yl-, 2-(hydroxymethyl)prop-2-en-1-yl-, (2Z)-but-2-en-1-yl-, prop-2-yn-1yl-, but-2-yn-1yl-, cyclohexylmethyl-, benzyl-, 3-cyanobenzyl-, 3-fluorobenzyl-, 3-chlorobenzyl-, 4-fluorobenzyl-, 4-chlorobenzyl-, 3-fluoro-5-(trifluoromethyl)benzyl-, 3-chloro-5-fluorobenzyl-, pyridin-4-yl-, 2-fluoropyridin-4-yl-, 2,3,5-trifluorobenzyl-, and 3,4,5-trifluorobenzyl-;

R 9 is a methyl or ethyl group; and

R 10 and R 11 are independently from each other, a group selected from a hydrogen atom and C 1 -C 6 -alkyl-,

or a salt or solvate thereof, or a salt of the solvate thereof.

8. The compound according to claim 1 , which is selected from the group consisting of:

(rac)-Ethyl [(3-{[4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]carbamate;

(rac)-Ethyl {[3-({4-[2-(benzyloxy)-4-fluorophenyl]-1,3,5-triazin-2-yl}amino)benzyl](methyl)oxido-λ 6 -sulfanylidene}carbamate;

(rac)-4-[2-(Benzyloxy)-4-fluorophenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

4-[2-(Benzyloxy)-4-fluorophenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 1;

4-[2-(Benzyloxy)-4-fluorophenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 2;

(rac)-Ethyl [(3-{[4-(4,5-difluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]carbamate;

(rac)-4-(4,5-Difluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-Ethyl [(3-{[4-(4-chloro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]carbamate;

(rac) 4-(4-Chloro-2-methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

4-(4-Chloro-2-methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 1;

4-(4-Chloro-2-methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 2;

(rac)-1-[(3-{[4-(4-Fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]-3-methylurea;

1-[(3-{[4-(4-Fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]-3-methylurea, enantiomer 1;

1-[(3-{[4-(4-Fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]-3-methylurea, enantiomer 2;

(rac)-Ethyl [(3-{[4-(2,2-difluoro-1,3-benzodioxol-4-yl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]carbamate;

(rac)-4-(2,2-Difluoro-1,3-benzodioxol-4-yl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-Ethyl [(3-{[4-(5-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]carbamate;

(rac)-4-(5-Fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

4-(5-Fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 1;

4-(5-Fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 2;

(rac)-N-[(3-{[4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]acetamide;

(rac)-Ethyl [(3-{[4-(2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]carbamate;

(rac)-4-(2-Methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

4-(2-Methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 1;

4-(2-Methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 2;

(rac)-Ethyl [(3-{[4-(3,4-dihydro-2H-chromen-8-yl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]carbamate;

(rac)-4-(3,4-Dihydro-2H-chromen-8-yl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

4-(3,4-Dihydro-2H-chromen-8-yl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 1;

4-(3,4-Dihydro-2H-chromen-8-yl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 2;

(rac)-Ethyl [(3-{[4-(2,3-dihydro-1-benzofuran-7-yl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]carbamate;

(rac)-4-(2,3-Dihydro-1-benzofuran-7-yl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

4-(2,3-Dihydro-1-benzofuran-7-yl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 1;

4-(2,3-Dihydro-1-benzofuran-7-yl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 2;

(rac)-Ethyl [(3-{[4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]carbamate;

(rac)-4-(2,3-Dihydro-1,4-benzodioxin-5-yl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

4-(2,3-Dihydro-1,4-benzodioxin-5-yl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 1;

4-(2,3-Dihydro-1,4-benzodioxin-5-yl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 2;

(rac)-N-{3-[(N,S-Dimethylsulfonimidoyl)methyl]phenyl}-4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-amine;

(rac)-Ethyl [{3-[(4-{2-[(4-fluorobenzyl)oxy]phenyl}-1,3,5-triazin-2-yl)amino]benzyl}(methyl)oxido-λ 6 -sulfanylidene]carbamate;

(rac)-4-{2-[(4-Fluorobenzyl)oxy]phenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-N-[(3-{[4-(4-Fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]methanesulfonamide;

(rac)-Ethyl [(3-{[4-(3-chloro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]carbamate;

(rac)-Ethyl {[3-({4-[5-fluoro-2-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]-1,3,5-triazin-2-yl}amino)benzyl](methyl)oxido-λ 6 -sulfanylidene}carbamate;

(rac)-Ethyl [methyl(oxido)(3-{[4-(2-phenoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)-λ 6 -sulfanylidene]carbamate;

(rac)-[(3-{[4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]cyanamide;

[(3-{[4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]cyanamide, enantiomer 1;

[(3-{[4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]cyanamide, enantiomer 2;

(rac)-Ethyl [(3-fluoro-5-{[4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]carbamate;

(rac)-4-(4-Fluoro-2-methoxyphenyl)-N-{3-fluoro-5-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

4-(4-Fluoro-2-methoxyphenyl)-N-{3-fluoro-5-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 1;

4-(4-Fluoro-2-methoxyphenyl)-N-{3-fluoro-5-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 2;

(rac)-4-[2-(Cyclohexylmethoxy)-4-fluorophenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-{4-Fluoro-2-[(4-fluorobenzyl)oxy]phenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-{4-Fluoro-2-[2-(tetrahydro-2H-pyran-4-yl)ethoxy]phenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-(4-Fluoro-2-methoxyphenyl)-N-(3-{[S-(tetrahydro-2H-pyran-4-yl)sulfonimidoyl]methyl}phenyl)-1,3,5-triazin-2-amine;

(rac)-N-{4-Chloro-3-[(S-methylsulfonimidoyl)methyl]phenyl}-4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-amine;

(rac)-Ethyl [{3-[(4-{2-[(3,4-dichlorobenzyl)oxy]phenyl}-1,3,5-triazin-2-yl)amino]benzyl}(methyl)oxido-λ 6 -sulfanylidene]carbamate;

(rac)-4-{2-[(3,4-Dichlorobenzyl)oxy]phenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-(4-Fluoro-2-{[( 2 H 5 )phenyl( 2 H 2 )methyl]oxy}phenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

4-[2-(1-cyclopentylethoxy)-4-fluorophenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-N-{3-Chloro-5-[(S-methylsulfonimidoyl)methyl]phenyl}-4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-amine;

(rac)-4-[4-Fluoro-2-(3,3,3-trifluoropropoxy)phenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-[4-Fluoro-2-(pyridin-3-ylmethoxy)phenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-[4-Fluoro-2-(pyridin-2-ylmethoxy)phenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-[4-Fluoro-2-(pyridin-4-ylmethoxy)phenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

4-{4-Fluoro-2-[1-(4-fluorophenyl)ethoxy]phenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, mixture of 4 stereoisomers;

(rac)-[(3-Fluoro-5-{[4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl-λ6-sulfanylidene]cyanamide;

[(3-Fluoro-5-{[4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl-λ6-sulfanylidene]cyanamide, enantiomer 1;

[(3-Fluoro-5-{[4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl-λ6-sulfanylidene]cyanamide, enantiomer 2;

(rac)-4-[2-(But-2-yn-1-yloxy)-4-fluorophenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

4-[2-(But-2-yn-1-yloxy)-4-fluorophenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 1;

4-[2-(But-2-yn-1-yloxy)-4-fluorophenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 2;

(rac)-4-[2-(2-Cyclopropylethoxy)-4-fluorophenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-[4-Fluoro-2-(prop-2-yn-1-yloxy)phenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

4-[4-Fluoro-2-(prop-2-yn-1-yloxy)phenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 1;

4-[4-Fluoro-2-(prop-2-yn-1-yloxy)phenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 2;

(rac)-4-{2-[(3,4-Difluorobenzyl)oxy]-4-fluorophenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-[4-Fluoro-2-(1,3-thiazol-5-ylmethoxy)phenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-{4-Fluoro-2-[(2-fluoropyridin-4-yl)methoxy]phenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

4-{4-Fluoro-2-[(2-fluoropyridin-4-yl)methoxy]phenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 1;

4-{4-Fluoro-2-[(2-fluoropyridin-4-yl)methoxy]phenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine, enantiomer 2;

(rac)-4-[4-Fluoro-2-(prop-2-en-1-yloxy)phenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-(4-Fluoro-2-{[4-(trifluoromethyl)benzyl]oxy}phenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-{2-[(4-Chlorobenzyl)oxy]-4-fluorophenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-(2-Ethoxy-4-fluorophenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-(4-Fluoro-2-{[3-fluoro-5-(trifluoromethyl)benzyl]oxy}phenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-{4-Fluoro-2-[(3-fluorobenzyl)oxy]phenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-(4-Fluoro-2-propoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-{2-[(3-Chlorobenzyl)oxy]-4-fluorophenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-[4-Fluoro-2-(1,2-oxazol-3-ylmethoxy)phenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-{2-[(3-Chloro-5-fluorobenzyl)oxy]-4-fluorophenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-[2-(2,2-Difluoroethoxy)-4-fluorophenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-{4-Fluoro-2-[(4-fluoro-3-methylbenzyl)oxy]phenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-{2-[(3-Chloro-4-fluorobenzyl)oxy]-4-fluorophenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-3-({5-Fluoro-2-[4-({3-[(S-methylsulfonimidoyl)methyl]phenyl}amino)-1,3,5-triazin-2-yl]phenoxy}methyl)benzonitrile;

(rac)-4-{4-Fluoro-2-[(2-methylprop-2-en-1-yl)oxy]phenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-[4-Fluoro-2-(4,4,4-trifluorobutoxy)phenyl]-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-{4-Fluoro-2-[(2,3,5-trifluorobenzyl)oxy]phenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-{2-[(2Z)-But-2-en-1-yloxy]-4-fluorophenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-{4-Fluoro-2-[(2,4,5-trifluorobenzyl)oxy]phenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-4-{4-Fluoro-2-[(3,4,5-trifluorobenzyl)oxy]phenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine;

(rac)-[(2,3-Difluoro-5-{[4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ 6 -sulfanylidene]cyanamide;

(rac)-N-{3,4-Difluoro-5-[(S-methylsulfonimidoyl)methyl]phenyl}-4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-amine;

(rac)-[Ethyl(3-{[4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)oxido-λ 6 -sulfanylidene]cyanamide;

(rac)-N-{3-[(S-ethylsulfonimidoyl)methyl]phenyl}-4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-amine;

N-{3-[(S-ethylsulfonimidoyl)methyl]phenyl}-4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-amine, enantiomer 1;

N-{3-[(S-ethylsulfonimidoyl)methyl]phenyl}-4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-amine, enantiomer 2;

(rac)-[(3-{[4-(4-Fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}-5 methylbenzyl)(methyl)oxido-λ 6 -sulfanylidene]cyanamide;

(rac)-2-({5-Fluoro-2-[4-({3-[(S-methylsulfonimidoyl)methyl]phenyl}amino)-1,3,5-triazin-2-yl]phenoxy}methyl)prop-2-en-1-ol; and

(rac)-[Cyclopropyl(3-{[4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)oxido-λ 6 -sulfanylidene]cyanamide,

or a salt or solvate thereof, or a salt of the solvate thereof.

9. A method for treatment of non-small cell lung carcinoma, comprising administering to a patient in need thereof the compound according to claim 1 , or a salt or solvate thereof, or a salt of the solvate thereof.

10. A pharmaceutical combination comprising the compound according claim 1 , or a salt or solvate thereof, or a salt of the solvate thereof, in combination with at least one or more additional active ingredients.

11. A pharmaceutical composition comprising the compound according to claim 1 , or a salt or solvate thereof, or a salt of the solvate thereof, in combination with an inert, nontoxic, pharmaceutically suitable adjuvant.

12. The compound according to claim 1 or a salt thereof.

13. The compound according to claim 8 or a salt thereof.

14. The pharmaceutical composition according to claim 11 comprising the compound of formula (I) or a salt thereof.

15. The method of claim 9 , comprising administering the compound of formula (I) or a salt thereof.